Ruxolitinib inhibits IFNγ-stimulated Sjogren's salivary gland MSC HLA-DR expression and chemokine-dependent T cell migration.

ABSTRACT:

Objectives

Sjögren's disease (SjD) is a systemic autoimmune disease characterized by focal lymphocytic infiltrate of salivary glands (SGs) and high SG IFNγ, both of which are associated with elevated lymphoma risk. IFNγ is also biologically relevant to mesenchymal stromal cells (MSCs), a SG resident cell with unique niche regenerative and immunoregulatory capacities. In contrast to the role of IFNγ in SjD, IFNγ promotes an anti-inflammatory MSC phenotype in other diseases. The objective of this study was to define the immunobiology of IFNγ-exposed SG-MSCs with and without the JAK1 & 2 inhibitor, ruxolitinib.

Methods

SG-MSCs were isolated from SjD and controls human subjects. SG-MSCs were treated with 10 ng/ml IFNγ +/- 1000 nM ruxolitinib. Experimental methods included flow c

SUBMITTER: McCoy SS 

PROVIDER: S-EPMC9536796 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature